Evidence map›Paper›PMID 31547879›Full record

ArticleStem cell research & therapy2019

S100B is required for maintaining an intermediate state with double-positive Sca-1+ progenitor and vascular smooth muscle cells during neointimal formation.

Yan Wu, Xin Liu, Ling-Yun Guo, Lei Zhang, Fei Zheng, Shan Li, Xing-Yuan Li, Ye Yuan, Yu Liu, Yu-Wen Yan and 4 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Phenotypic Switching of VSMCs in the Development of CVDs: Focus on miRs.International journal of molecular sciences · 2025
    Review
  4. S100 proteins in cardiovascular diseases.Molecular medicine (Cambridge, Mass.) · 2023
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Moderate Alcohol Consumption Targets S100βAlcoholism, clinical and experimental research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Yan WuDepartment of Physiology, School of Basic Medicine Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Xin LiuLaboratory Animal Center, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Ling-Yun GuoInstitute of Clinical Medicine and Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Lei ZhangInstitute of Clinical Medicine and Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Fei ZhengInstitute of Clinical Medicine and Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Shan LiDepartment of Biochemistry, School of Basic Medicine Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Xing-Yuan LiDepartment of Physiology, School of Basic Medicine Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Ye YuanInstitute of Clinical Medicine and Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Yu LiuInstitute of Clinical Medicine and Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Yu-Wen YanDepartment of Physiology, School of Basic Medicine Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Shi-You ChenDepartment of Physiology & Pharmacology, The University of Georgia, Athens, GA, 30602, USA.
Jia-Ning WangInstitute of Clinical Medicine and Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Jin-Xuan ZhangDepartment of Physiology, School of Basic Medicine Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China. tangjm416@163.com.
Jun-Ming TangDepartment of Physiology, School of Basic Medicine Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China. 422729594@qq.com.ORCID 0000-0002-1591-7626
Hubei University of Medicine · CNUniversity of Georgia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAccumulation of vascular smooth muscle cells (VSMCs) within the neointimal region is a hallmark of atherosclerosis and vessel injury. Evidence has shown that Sca-1-positive (Sca-1+) progenitor cells residing in the vascular adventitia play a crucial role in VSMC assemblages and intimal lesions. However, the underlying mechanisms, especially in the circumstances of vascular injury, remain unknown. METHODS AND

resultsThe neointimal formation model in rats was established by carotid artery balloon injury using a 2F-Forgaty catheter. Most Sca-1+ cells first appeared at the adventitia of the vascular wall. S100B expressions were highest within the adventitia on the first day after vessel injury. Along with the sequentially increasing trend of S100B expression in the intima, media, and adventitia, respectively, the numbers of Sca-1+ cells were prominently increased at the media or neointima during the time course of neointimal formation. Furthermore, the Sca-1+ cells were markedly increased in the tunica media on the third day of vessel injury, SDF-1α expressions were obviously increased, and SDF-1α levels and Sca-1+ cells were almost synchronously increased within the neointima on the seventh day of vessel injury. These effects could effectually be reversed by knockdown of S100B by shRNA, RAGE inhibitor (SPF-ZM1), or CXCR4 blocker (AMD3100), indicating that migration of Sca-1+ cells from the adventitia into the neointima was associated with S100B/RAGE and SDF-1α/CXCR4. More importantly, the intermediate state of double-positive Sca-1+ and α-SMA cells was first found in the neointima of injured arteries, which could be substantially abrogated by using shRNA for S100B or blockade of CXCR4. S100B dose-dependently regulated SDF-1α expressions in VSMCs by activating PI3K/AKT and NF-κB, which were markedly abolished by PI3K/AKT inhibitor wortmannin and enhanced by p65 blocker PDTC. Furthermore, S100B was involved in human umbilical cord-derived Sca-1+ progenitor cells' differentiation into VSMCs, especially in maintaining the intermediate state of double-positive Sca-1+ and α-SMA.

conclusionsS100B triggered neointimal formation in rat injured arteries by maintaining the intermediate state of double-positive Sca-1+ progenitor and VSMCs, which were associated with direct activation of RAGE by S100B and indirect induction of SDF-1α by activating PI3K/AKT and NF-κB.

Indexed as

AdventitiaAnimalsAtaxin-1Carotid Artery InjuriesCells, CulturedHumansMuscle, Smooth, VascularMyoblastsMyocytes, Smooth MuscleNF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRatsRats, Sprague-DawleyRegenerationS100 Calcium Binding Protein beta SubunitAtaxin-1NF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktS100 Calcium Binding Protein beta SubunitIntermediate stateNeointimaNF-κBS100BSca-1SDF-1α

Identifiers

PMID31547879
PMCPMC6757428
OpenAlexW2975805567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.